Streetbeat News

Analyst Ratings

REXR

Mizuho analyst Vikram Malhotra maintains a Neutral rating on Rexford Industrial Realty (NYSE:REXR) and lowers the price target from $50 to $49.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:01 pm

CE

In the past three months, 17 analysts have rated Celanese (NYSE:CE), with a mix of bullish and bearish views. Recent ratings show a decline in the average 12-month price target from $169.29 to $155.65. Analysts have generally lowered their ratings and price targets, reflecting concerns over Celanese's financial performance, including a 5.15% revenue decline and challenges in debt management.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 12:01 pm

ATI

Analysts have recently evaluated ATI (NYSE:ATI), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $75.43, reflecting an 8.69% rise from the previous target. Analysts have raised their ratings and price targets, indicating positive sentiment towards ATI's financial performance, including strong revenue growth and profitability. However, the company faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 12:01 pm

CRWD

In the past three months, 48 analysts have rated CrowdStrike Holdings (NASDAQ:CRWD), with a mix of bullish and bearish perspectives. The average 12-month price target has decreased by 10.82% to $324.15. Analysts have adjusted their ratings and price targets, reflecting a negative shift in sentiment. Despite this, CrowdStrike shows strong revenue growth and net margin, though it faces challenges with ROE and ROA.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 12:01 pm

SOLV

Analysts have mixed ratings for Solventum (NYSE:SOLV), with recent assessments showing a decrease in average price targets. The company's financial health is strong, but it faces higher financial risk due to a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 12:00 pm

COLL

Collegium Pharmaceutical (NASDAQ:COLL) has received mixed analyst ratings, with a majority being bullish. The average 12-month price target has increased to $44.0, up from $42.0. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Collegium's financials show strong net margins and ROE, but high debt levels pose challenges.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 12:00 pm

SPGI

S&P Global (NYSE:SPGI) has been analyzed by 13 analysts, with most ratings being somewhat bullish. The average 12-month price target has increased by 4.93% to $539.54. Analysts have raised their ratings and price targets, reflecting positive sentiment. S&P Global shows strong financial metrics, including a 14.45% revenue growth rate and a 28.49% net margin.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 12:00 pm

FR

Mizuho analyst Vikram Malhorta maintains an Outperform rating on First Industrial Realty (NYSE:FR) and raises the price target from $58 to $62.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:00 pm

CXM

Keybanc analyst Jason Ader maintains an Overweight rating on Sprinklr (NYSE:CXM) but lowers the price target from $16 to $12.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 11:59 am

SOLV

BTIG analyst Ryan Zimmerman has initiated coverage on Solventum (NYSE:SOLV) with a Neutral rating.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 11:57 am